PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS

被引：0
|
作者：
Khan, Muhammad [1 ]
机构：
[1] DOW Univ Hosp, Karachi, Pakistan
来源：
TRANSPLANT INTERNATIONAL | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
MP077
引用
收藏
页码：295 / 295
页数：1
相关论文
共 50 条
  • [1] PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS
    Khan, Muhammad Tassaduq
    SWISS MEDICAL WEEKLY, 2019, : 19S - 19S
  • [2] A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients
    Reischig, Tomas
    Vlas, Tomas
    Kacer, Martin
    Pivovarcikova, Kristyna
    Lysak, Daniel
    Nemcova, Jana
    Drenko, Petr
    Machova, Jana
    Bouda, Mirko
    Sedivcova, Monika
    Kormunda, Stanislav
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 34 (05): : 920 - 934
  • [3] Randomized trial of preemptive valganciclovir therapy versus valacyclovir prophylaxis for the management of cytomegalovirus infection in kidney transplant recipients.
    Reischig, Tomas
    Jindra, Pavel
    Klaboch, Jan
    Svecova, Miroslava
    Hes, Ondrej
    Treska, Vladislav
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 506 - 506
  • [4] Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients
    Singh, N
    CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) : 742 - 751
  • [5] VALGANCICLOVIR PROPHYLAXIS VERSUS PREEMPTIVE THERAPY FOR PREVENTION OF CYTOMEGALOVIRUS IN RENAL TRANSPLANT RECIPIENTS: A RANDOMIZED CONTROLLED TRIAL
    Reischig, Tomas
    Kacer, Martin
    Vlas, Tomas
    Machova, Jana
    Kielberger, Lukas
    Richtrova, Pavlina
    Jindra, Pavel
    Lysak, Daniel
    Hes, Ondrej
    Pivovarcikova, Kristyna
    Bouda, Mirko
    Nemcova, Jana
    TRANSPLANT INTERNATIONAL, 2021, 34 : 190 - 190
  • [6] Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients
    Bodro, Marta
    Sabe, Nuria
    Llado, Laura
    Baliellas, Carme
    Niubo, Jordi
    Castellote, Jose
    Fabregat, Joan
    Rafecas, Antoni
    Carratala, Jordi
    LIVER TRANSPLANTATION, 2012, 18 (09) : 1093 - 1099
  • [7] Comparison of universal prophylaxis and preemptive treatment with valganciclovir in management of cytomegalovirus infection in heart transplant recipients
    Vymetalova, Jevgenija
    Kubanek, Milos
    Gazdic, Tomas
    Vrbska, Jana
    Malek, Ivan
    Kautzner, Josef
    COR ET VASA, 2012, 54 (01) : E16 - E21
  • [8] Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients
    Blanco, Noemie Boillat
    Pascual, Manuel
    Venetz, Jean-Pierre
    Nseir, Ghaleb
    Meylan, Pascal R.
    Manuel, Oriol
    TRANSPLANTATION, 2011, 91 (02) : 251 - 255
  • [9] Prophylaxis Versus Preemptive Therapy for Prevention of Human Cytomegalovirus Disease in Pediatric Liver Transplant Recipients
    Gerna, Giuseppe
    Lilleri, Daniele
    Torre, Giuliano
    TRANSPLANTATION, 2009, 87 (02) : 306 - 307
  • [10] Valganciclovir prophylaxis for cytomegalovirus disease in kidney and simultaneous pancreas-kidney transplant recipients.
    Ciancio, G
    Burke, G
    Suzart, K
    Vaidya, A
    Roth, D
    Kupin, W
    Mattiazzi, A
    Miller, J
    JOURNAL OF UROLOGY, 2002, 167 (04): : 371 - 371
12345